Diabetic Macular Edema (DME) Research & Clinical Trials

Share:

Sponsor - Allergan (Recruitment/Not Yet Open)

Study: ACACIA
AbiCipar pegol safety and efficacy in pAtients with Centrally-Involved diabetic macular edemA

Sponsor – Genentech/Roche (Recruiting/Open To Enrollment)

Study: BOULEVARD
A MULTIPLE-CENTER, MULTIPLE-DOSE, RANDOMZED, ACTIVE COMPARATOR-CONTROLLED, DOUBLE-MASKED, PARALLEL GROUP, 28-WEEK STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF R06867461 ADMINISTERED INTRAVITREALLY IN PATIENTS WITH DIABETIC MACULAR EDEMA
https://clinicaltrials.gov/ct2/show/NCT02699450?term=BP30099&rank=1

Sponsor – Regeneron (Closed to Enrollment)

Study: RUBY
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED, PHASE 2 STUDY OF THE EFFICACY, SAFETY, AND TOLERABILITY OF REPEATED DOSES OF INTRAVITREAL REGN910-3 IN PATIENTS WITH DIABETIC MACULAR EDEMA
https://clinicaltrials.gov/ct2/show/NCT02712008?term=RUBY&rank=3

Previous Diabetic Macular Edema (DME) Studies:

Sub-Investigator, 2008 - 2010
A 26-Week, Open-Label Study to Assess the Safety and Efficacy of 700µg Dexamethasone Posterior Segment Drug Delivery System Applicator System in the Treatment of Vitrectomized Subjects with Diabetic Macular Edema

Sub-Investigator, 2008 - 2010
A Phase 2, Randomized, Double-Masked, Placebo-Controlled, Dose-Ranging Clinical Study to Access the Safety and Efficacy of Subconjuctival Injections of Sirolimus in Patients with Diabetic Macular Edema Secondary to Diabetic Retinopathy

Sub-Investigator, 2008 - 2010
A 52-Week, Masked, Multicenter, Randomized, Controlled Trial (With Up To 13 Weeks Additional Follow-up) to Assess the Safety and Efficacy of 700µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System in Combination with Laser Photocoagulation Compared with Laser Photocoagulation Alone in the Treatment of Subjects With Diffuse Diabetic Macular Edema (DME)

Sub-Investigator, 2007 - 2012 
RISE - A Phase 3, Double-Masked, Multicenter, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection in Subjects with Clinically Significant Macular Edema with Center Involvement Secondary to Diabetes Mellitus

Sub-Investigator, 2007 - 2011 
An Open Label Pharmacokinetic and Efficacy Study of 0.5µg/day and 0.2µg/day Flucinolone Acetonide Intravitreal Inserts in Subjects with Diabetic Macular Edema

Sub-Investigator, 2006 - 2011
FAME - A Randomized, Double-Masked, Parallel Group, Multi-center, Dose-Finding Comparison of the Safety and Efficacy of ASI-001A 0.5µg/day and ASI-001B .02µg/day Fluocinolone Acetonide Intravitreal Inserts to Sham Injection in Subjects with Diabetic Macular Edema

Sub-Investigator, 2003
Reduction in the Occurrence of Center-Treatment Diabetic Macular Edema.